View Financial HealthNewcelX 配当と自社株買い配当金 基準チェック /06NewcelX配当金を支払った記録がありません。主要情報n/a配当利回り-15.3%バイバック利回り総株主利回り-15.3%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 01NewcelX Ltd. announced that it has received $1.349994 million in fundingOn April 30, 2026, NewcelX Ltd. closed the transaction.お知らせ • Apr 02NewcelX Ltd. announced that it expects to receive $1.349994 million in fundingNewcelX Ltd. announced that it has entered into a securities purchase agreement to issue 490,907 common shares or pre-funded warrants at an issue price of $2.75 per share for gross proceeds of $1,349,994.25 and one series of warrants to purchase 687,270 common shares at an exercise price of $3.025 per share for aggregate proceeds of $1,349,994.25 on April 1, 2026. The offering includes participation from existing shareholders and is expected to close on or about April 15, 2026, subject to the satisfaction of customary closing conditions. The securities are being issued in a private placement under section 4(a)(2) of the securities act of 1933, as amended), and Regulation D promulgated thereunder and have not been registered under the securities act, or applicable state securities laws.New Risk • Mar 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.57m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$8.57m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change).New Risk • Mar 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪2.2m free cash flow). Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (US$11.9m market cap).お知らせ • Jan 13Newcelx Ltd. Announces Positive Results from International Collaborative StudyNewcelX Ltd. reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell-derived islets for the treatment of Type 1 Diabetes. The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the University of Technology Sydney, the University of Wisconsin-Madison, Monash University, the Queensland University of Technology, and the Australian Foundation for Diabetes Research (AFDR), examined the use of engineered scaffolds incorporating extracellular matrix (ECM) derived from a decellularized human pancreas. The work evaluated whether ECM integration could support the function of encapsulated pluripotent stem cell-derived islets within a removable delivery system. The study results demonstrated that when ECM was incorporated into the scaffold, implanted islets exhibited functional performance comparable to encapsulated islets delivered without a scaffold. These findings suggest that biomaterial design and tissue microenvironment play a critical role in supporting islet function and may enable safer, retrievable delivery configurations for future therapeutic development. The research was supported through a Type 1 Diabetes research initiative led by the Australian Foundation for Diabetes Research, which had received donor matched funding for the published study from the National Stem Cell Foundation of Australia. Moreover, it has received dedicated funding from Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes research and advocacy organization, to further develop the underlying model based on the study results. The program integrates proprietary cell differentiation protocols with immune-protective and delivery-oriented design features, with the goal of achieving functional insulin secretion without the need for systemic immunosuppression.お知らせ • Jan 05NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory BoardNewcelX Ltd. announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership, to its Scientific Advisory Board. Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap pharma company, where he oversees the strategic development of next-generation diabetes technologies, clinical programs, and real-world evidence initiatives. His background includes connected-care innovation, advanced insulin-management systems, and the integration of therapeutic and digital solutions to enhance patient outcomes. In joining the NewcelX Scientific Advisory Board, Dr. Boisdron will provide high-level strategic guidance supporting the development of IsletRx, NewcelX's lead therapeutic program, a stem-cell-derived islet cell therapy for insulin-dependent Type 1 Diabetes. Dr. Boisdron will advise on translational strategy as NewcelX advances the program toward clinical trials, including patient-adoption considerations, health-system integration, and future global commercialization frameworks.New Risk • Dec 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.75m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪2.2m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$9.75m market cap).お知らせ • Nov 18NewcelX Ltd. Announces Appointment of Prof. Jeremy Shefner to the Scientific Advisory BoardNewcelX Ltd. announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board. Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and research of neurological diseases that is home to one of the largest multidisciplinary brain and spine programs in the United States and the world's largest Phase 0 clinical trials program advancing innovative neurotherapeutics Link. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS) and has published more than 200 peer-reviewed papers on ALS biomarkers, clinical trial design and outcome measures Link. In his role on the SAB of NewcelX, Prof. Shefner will provide strategic guidance on the Company's programs in ALS, including the clinical development of AstroRx, and will support the integration of neuromuscular and neurodegenerative disease expertise into the Company's broader platform of cell therapy and neuroscience innovation.お知らせ • Nov 07NewcelX Ltd. Appoints Tamir Ben-Hur as Scientific Advisory BoardNewcelX Ltd. announced that Professor Tamir Ben-Hur, MD, PhD, a renowned neurologist and long-time scientific advisor of Kadimastem Ltd., will join the Company's Scientific Advisory Board. Prof. Ben-Hur, a Professor of Neurology at Hadassah University Medical Center and the Hebrew University of Jerusalem, is widely recognized as a global expert in neuroimmunology and stem-cell-based regenerative medicine. The commitment of Prof. Ben-Hur to join the NewcelX Scientific Advisory Board represents a strong endorsement of the Merger and the scientific foundation on which NewcelX is being built — uniting Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with NLS Pharmaceutic Ltd.'s expertise in central nervous system therapeutics.Board Change • Nov 03Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 2 independent directors (4 non-independent directors). Independent External Director Liora Oren was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.決済の安定と成長配当データの取得安定した配当: NCELの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: NCELの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場NewcelX 配当利回り対市場NCEL 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (NCEL)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.5%アナリスト予想 (NCEL) (最長3年)n/a注目すべき配当: NCELは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: NCELは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: NCELの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: NCELが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 21:55終値2026/05/11 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NewcelX Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 01NewcelX Ltd. announced that it has received $1.349994 million in fundingOn April 30, 2026, NewcelX Ltd. closed the transaction.
お知らせ • Apr 02NewcelX Ltd. announced that it expects to receive $1.349994 million in fundingNewcelX Ltd. announced that it has entered into a securities purchase agreement to issue 490,907 common shares or pre-funded warrants at an issue price of $2.75 per share for gross proceeds of $1,349,994.25 and one series of warrants to purchase 687,270 common shares at an exercise price of $3.025 per share for aggregate proceeds of $1,349,994.25 on April 1, 2026. The offering includes participation from existing shareholders and is expected to close on or about April 15, 2026, subject to the satisfaction of customary closing conditions. The securities are being issued in a private placement under section 4(a)(2) of the securities act of 1933, as amended), and Regulation D promulgated thereunder and have not been registered under the securities act, or applicable state securities laws.
New Risk • Mar 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.57m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$8.57m market cap). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change).
New Risk • Mar 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪2.2m free cash flow). Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (US$11.9m market cap).
お知らせ • Jan 13Newcelx Ltd. Announces Positive Results from International Collaborative StudyNewcelX Ltd. reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell-derived islets for the treatment of Type 1 Diabetes. The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the University of Technology Sydney, the University of Wisconsin-Madison, Monash University, the Queensland University of Technology, and the Australian Foundation for Diabetes Research (AFDR), examined the use of engineered scaffolds incorporating extracellular matrix (ECM) derived from a decellularized human pancreas. The work evaluated whether ECM integration could support the function of encapsulated pluripotent stem cell-derived islets within a removable delivery system. The study results demonstrated that when ECM was incorporated into the scaffold, implanted islets exhibited functional performance comparable to encapsulated islets delivered without a scaffold. These findings suggest that biomaterial design and tissue microenvironment play a critical role in supporting islet function and may enable safer, retrievable delivery configurations for future therapeutic development. The research was supported through a Type 1 Diabetes research initiative led by the Australian Foundation for Diabetes Research, which had received donor matched funding for the published study from the National Stem Cell Foundation of Australia. Moreover, it has received dedicated funding from Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes research and advocacy organization, to further develop the underlying model based on the study results. The program integrates proprietary cell differentiation protocols with immune-protective and delivery-oriented design features, with the goal of achieving functional insulin secretion without the need for systemic immunosuppression.
お知らせ • Jan 05NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory BoardNewcelX Ltd. announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership, to its Scientific Advisory Board. Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap pharma company, where he oversees the strategic development of next-generation diabetes technologies, clinical programs, and real-world evidence initiatives. His background includes connected-care innovation, advanced insulin-management systems, and the integration of therapeutic and digital solutions to enhance patient outcomes. In joining the NewcelX Scientific Advisory Board, Dr. Boisdron will provide high-level strategic guidance supporting the development of IsletRx, NewcelX's lead therapeutic program, a stem-cell-derived islet cell therapy for insulin-dependent Type 1 Diabetes. Dr. Boisdron will advise on translational strategy as NewcelX advances the program toward clinical trials, including patient-adoption considerations, health-system integration, and future global commercialization frameworks.
New Risk • Dec 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.75m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪2.2m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-₪51m). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$9.75m market cap).
お知らせ • Nov 18NewcelX Ltd. Announces Appointment of Prof. Jeremy Shefner to the Scientific Advisory BoardNewcelX Ltd. announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board. Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and research of neurological diseases that is home to one of the largest multidisciplinary brain and spine programs in the United States and the world's largest Phase 0 clinical trials program advancing innovative neurotherapeutics Link. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS) and has published more than 200 peer-reviewed papers on ALS biomarkers, clinical trial design and outcome measures Link. In his role on the SAB of NewcelX, Prof. Shefner will provide strategic guidance on the Company's programs in ALS, including the clinical development of AstroRx, and will support the integration of neuromuscular and neurodegenerative disease expertise into the Company's broader platform of cell therapy and neuroscience innovation.
お知らせ • Nov 07NewcelX Ltd. Appoints Tamir Ben-Hur as Scientific Advisory BoardNewcelX Ltd. announced that Professor Tamir Ben-Hur, MD, PhD, a renowned neurologist and long-time scientific advisor of Kadimastem Ltd., will join the Company's Scientific Advisory Board. Prof. Ben-Hur, a Professor of Neurology at Hadassah University Medical Center and the Hebrew University of Jerusalem, is widely recognized as a global expert in neuroimmunology and stem-cell-based regenerative medicine. The commitment of Prof. Ben-Hur to join the NewcelX Scientific Advisory Board represents a strong endorsement of the Merger and the scientific foundation on which NewcelX is being built — uniting Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with NLS Pharmaceutic Ltd.'s expertise in central nervous system therapeutics.
Board Change • Nov 03Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. 2 independent directors (4 non-independent directors). Independent External Director Liora Oren was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.